|Dr. Scott N. Braunstein||CEO, Pres & Director||898.88k||N/A||1963|
|Mr. Edward F. Smith CPA||Consultant||570.09k||N/A||1971|
|Dr. Joseph Hulihan M.D.||Chief Medical Officer||488.87k||N/A||1956|
|Mr. Steven E. Pfanstiel C.M.A., M.B.A.||CFO & Treasurer||N/A||N/A||1973|
|Ms. Sasha Damouni Ellis||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Martha E. Manning||VP, Gen. Counsel & Sec.||N/A||N/A||1955|
|Mr. Thomas J. Lyons||VP of Corp., Bus. Devel. & Commercial Planning||N/A||N/A||N/A|
|Ms. Lisa Lejuwaan||VP of Sales||N/A||N/A||N/A|
|Ms. Rose McKinley||VP of HR & Organizational Devel.||N/A||N/A||N/A|
|Dr. Alex Aimetti||Head of Scientific Affairs||N/A||N/A||N/A|
Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, and postpartum depression. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Marinus Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 9. The pillar scores are Audit: 5; Board: 9; Shareholder Rights: 6; Compensation: 7.